Development of an on-line immobilized α-glucosidase microreactor coupled to liquid chromatography for screening of α-glucosidase inhibitors.

J Pharm Biomed Anal

Henan International Joint Laboratory of Medicinal Plants Utilization, College of Chemistry and Chemical Engineering, Henan University, Kaifeng, 475004, China. Electronic address:

Published: February 2020

In order to rapidly screen α-glucosidase (α-GLU) inhibitors from Chinese herbs extract, an online screening method was developed by using enzymatic microreactors in combination with HPLC. A type of dodecahedral and porous material (ZIF-90) was synthesized at room temperature and employed as supports to construct enzymatic microreactor. The amount of α-glucosidase immobilized on ZIF-90 was 58.65 μg per mg carrier under the optimized conditions. In the online screening process, the eluent of 30 s was selected for detection. For the application of this on-line screening system, three α-glucosidase inhibitors with known structure (2,4-dimethoxy-6,7-dihydroxyphenanthrene, batatasin I, 3,5-dimethoxy-2'-hydroxyaiaryl) were selectively extracted from Dioscorea opposita Thunb. Three compounds screened from honeysuckle leaves were isochlorogenic acid B, 1,5-dicaffeoylquinic acid and isochlorogenic acid C, respectively. Two compounds including (+)-catechin and (-)-epigallocatechin gallate were screened from Xinyang Maojian tea. Three unknown ingredients were also screened out from Radix Rehmanniae Praeparata. The nanomaterials in the microreactor can be conveniently replaced. The screening flow rate and elution time can be easily adjusted and controlled by microinjection pump. Considering the specificity of enzyme binding and convenience of online screening system, this method has great potential for fast real-time fishing of α-glucosidase inhibitors from Chinese herbal medicines.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jpba.2019.113047DOI Listing

Publication Analysis

Top Keywords

α-glucosidase inhibitors
12
online screening
12
inhibitors chinese
8
screening system
8
isochlorogenic acid
8
α-glucosidase
6
screening
6
development on-line
4
on-line immobilized
4
immobilized α-glucosidase
4

Similar Publications

Drug Development.

Alzheimers Dement

December 2024

GSK R&D, Stevenage, Hertfordshire, United Kingdom.

Background: Genetic variants in GRN, the gene encoding progranulin, are causal for or are associated with the risk of multiple neurodegenerative diseases. Modulating progranulin has been considered as a therapeutic strategy for neurodegenerative diseases including Frontotemporal Dementia (FTD) and Alzheimer's Disease (AD). Here, we integrated genetics with proteomic data to determine the causal human evidence for the therapeutic benefit of modulating progranulin in AD.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

ECU, Perth, Western Australia, Australia.

Background: The autophagy lysosomal pathway (ALP) and the ubiquitin-proteasome system (UPS) are key proteostasis mechanisms in cells, which are dysfunctional in AD and linked to protein aggregation and neuronal death. Autophagy is over activated in Alzheimer's disease brain whereas UPS is severely impaired. Activating autophagy has received most attention, however recent evidence suggests that UPS can clear aggregate proteins and a potential therapeutic target for AD and protein misfolding diseases.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Fundacion Neuropolis, Zaragoza, Zaragoza, Spain.

Background: The therapeutic management of dementia with Lewy bodies (LBD) is a challenge given the high sensitivity to drugs in this disease. This is particularly sensitive with regard to the management of parkinsonism. In particular, treatment of motor symptoms with levodopa or dopaminergic agonists poses a risk of worsening cognitive and behavioral symptoms.

View Article and Find Full Text PDF

Background: Genetic studies indicate a causal role for microglia, the innate immune cells of the central nervous system (CNS), in Alzheimer's disease (AD). Despite the progress made in identifying genetic risk factors, such as CD33, and underlying molecular changes, there are currently limited treatment options for AD. Based on the immune-inhibitory function of CD33, we hypothesize that inhibition of CD33 activation may reverse microglial suppression and restore their ability to resolve inflammatory processes and mitigate pathogenic amyloid plaques, which may be neuroprotective.

View Article and Find Full Text PDF

Background: Our previous study identified that Sildenafil (a phosphodiesterase type 5 [PDE5] inhibitor) is a candidate repurposable drug for Alzheimer's Disease (AD) using in silico network medicine approach. However, the clinically meaningful size and mechanism-of-actions of sildenafil in potential prevention and treatment of AD remind unknown.

Method: We conducted new patient data analyses using both the MarketScan® Medicare with Supplemental database (n = 7.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!